ERBB2 and gastric cancer: The combination of zolbetuximab and CAPOX has the potential to serve as a novel first-line treatment option for patients diagnosed with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic GC, and GEJ [190].